<DOC>
	<DOCNO>NCT01097252</DOCNO>
	<brief_summary>Three weekly cisplatin base chemoradiation compare compliance , toxicity , response rate weekly cisplatin base chemoradiation treatment locoregionally advanced cervical cancer .</brief_summary>
	<brief_title>Weekly Versus Three-week Chemoradiation Patients With Advanced Cervical Cancer</brief_title>
	<detailed_description>This study compare compliance , toxicity , response survival rate concurrent chemoradiation weekly cisplatin 40mg/m2 three-week cisplatin 75mg/m2 patient advanced cervical cancer . Patients primary untreated invasive squamous cell carcinoma , adenosquamous carcinoma adenocarcinoma cervix stage IIB IVA enrol . Patients histologically proven locoregionally advanced cervical cancer randomize two treatment arm ; Arm I , concurrent chemoradiation weekly cisplatin 40mg/m2 six time ; Arm II , concurrent chemoradiation three-week cisplatin 75mg/m2 three time . The compliance toxicity chemoradiation primary endpoint . Response rate overall survival analyze secondary endpoint .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven cervical cancer Squamous , Adenosquamous , Adeno carcinoma cell type International Federation Gynecologic Oncology ( FIGO ) stage IIB IVA Gynecologic Oncology Group ( GOG ) performance status 0 2 Previous history chemotherapy radiation History cancer Hypersensitivity platinum agent Pregnancy Serious medical disease</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cervical Neoplasm</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>compliance</keyword>
	<keyword>toxicity</keyword>
</DOC>